Evaluating a new imaging technique for lung disease linked to connective tissue disorders
Clinical Study of 18F Labeled Probe Targeting Fibroblast Activating Protein and Integrin avβ3 (FAPI-RGD) in Interstitial Lung Disease Associated With Connective Tissue Disease
Sichuan Provincial People's Hospital · NCT06143540
This study is testing a new imaging method to see if it can help doctors better understand lung disease in people with connective tissue disorders.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital (other) |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT06143540 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the clinical utility of 18F-FAPI-RGD PET/CT imaging in patients with interstitial lung disease associated with connective tissue diseases. Participants will undergo a clinical evaluation followed by a PET/CT examination using the 18F-FAPI-RGD tracer, which targets specific proteins related to lung inflammation and fibrosis. The study will analyze the correlation between imaging results and various clinical parameters, including lung function and laboratory indicators.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and above who have been diagnosed with or are highly suspected of having interstitial lung disease associated with connective tissue diseases.
Not a fit: Patients who are pregnant, breastfeeding, or have other significant respiratory diseases or abnormal cardiopulmonary function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the diagnosis and management of interstitial lung disease in patients with connective tissue disorders.
How similar studies have performed: While the use of PET imaging in lung diseases is established, the specific application of 18F-FAPI-RGD in this context is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 and above * Patients who have been diagnosed with, or are clinically highly suspected of ILD * Patients who have been diagnosed with, or are clinically highly suspected of CTD-ILD Exclusion Criteria: * Pregnant or breastfeeding * Patients with tumor, other respiratory diseases, and lung surgery * Abnormal cardiopulmonary function or mental state, unable tolerate PET/CT
Where this trial is running
Chengdu, Sichuan
- Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Interstitial Lung Disease